화학공학소재연구정보센터
홈 로그인 로그아웃 연락처 사이트맵
Polymer(Korea), Vol.32, No.3, 284-289, May, 2008
Export Citation
쥐 경동맥 손상 모델에서 Poly(n-butylmethacrylate) 혹은 Poly(3-hydroxybutyrate-co-4-hydroxybutyrate)를 이용한 Paclitaxel 국소 전달 요법의 신생내막 형성 억제 효과
Inhibition of Intimal Hyperplasia by Perivascular Delivery of Paclitaxel Using Poly(n-butylmethacrylate) or Poly(3-hydroxybutyrate-co-4-hydroxybutyrate) in Balloon-Injured Rat Carotid Arteries
권진숙, 이호연1, 허신행1, 박노관, 심태진, 김유경, 김범수1, 김동운†
  • 충북대학교 의과대학 내과학교실
  • 1충북대학교 공과대학 화학공학부
Jin-Sook Kwon, Ho-Yeon Lee1, Shin-Haeng Heo1, Rho-Kwan Park, Tae-Jin Shim, Yu-Kyug Kim, Beom Soo Kim1, and Dong-Woon Kim†
  • Department of Internal Medicine, College of Medicine, Chungbuk National University, Cheongju, Chungbuk 361-763, Korea
  • 1Department of Chemical Engineering, College of Engineering, Chungbuk National University, Cheongju, Chungbuk 361-763, Korea
E-mail:
초록
Poly(n-butylmethacrylate)(PBMA)와 poly(3-hydroxybutyrate-co-4-hydroxybutyrate) (PHA)가 혈관 협착 방지를 위한 국소 약물 요법시 유용한 고분자인지 검정하였다. 10% paclitaxel 함유 필름으로부터 방출되는 paclitaxel은 초기 1주간은 빠르게, 30일까지는 중증도로, 이후는 천천히 방출되었다. Paclitaxel 함유 필름들은 풍선 손상을 가한 쥐 경동맥의 신생내막 증식을 억제하였다 (PBMA vs contol：0.03±0.02 vs 0.10±0.01 mm2, p<0.05; PHA vs control: 0.04±0.03 vs 0.09±0.01 mm2, p<0.05). PBMA와 PHA는 혈관 협착 방지를 위한 약물 전달 고분자로 유용할 것으로 사료된다. 고분자 필름은 혈관 외벽에 장착이 용이한 경우 사용될 수 있다. 또한, 이 고분자들은 약물 방출 스텐트 개발시 이용될 수 있다.
Polymer is a critical component of local drug delivery to prevent restenosis. This study tested whether poly(n-butylmethacrylate)(PBMA) and poly(3-hydroxybutyrate-co-4-hydroxybutyrate) (PHA) was candidates for this purpose. In vitro release of paclitaxel from PBMA and PHA loaded with 10% paclitaxel exhibited a triphasic release profile, with a fast initial and intermediate second phase followed by a slow release phase. Perivascular delivery of paclitaxel using these films inhibited neointimal hyperplasia in balloon-injured rat carotid arteries. The paclitaxel-loaded PBMA or PHA groups showed significant neointimal formation reductions versus the control groups (PBMA vs contol: 0.03±0.02 vs 0.10±0.01 mm2, p<0.05; PHA vs contol: 0.04±0.03 vs 0.09±0.01 mm2, p<0.05). This study suggests that PBMA and PHA could be good candidate polymers of local drug delivery to prevent restenosis. Perivascular delivery using these films represents a possible approach for prevention of restenosis. These can be candidate polymers for drug eluting stents.
Keywords:restenosis;drug delivery systems;polymers;paclitaxel
  1. Popma JJ, Califf RM, Topol EJ, Circulation, 84, 1426 (1991)
  2. Groote P, Bauters C, McFadden EP, Lablanche JM, Leroy F, Bertrand ME, Circulation, 91, 968 (1995)
  3. Forrester JS, Fishbein M, Helfant R, Fagin J, J. Am. Coll. Cardiol., 17, 758 (1991)
  4. Currier JW, Faxon DP, J. Am. Coll. Cardiol., 25, 516 (1995)
  5. Farb A, Heller PF, Shroff S, Cheng L, Kolodgie FD, Carter AJ, Scott DS, Froehlich J, Virmani R, Circulation, 104, 473 (2001)
  6. Gershlick A, De Scheerder I, Chevalier B, Stephens-Lloyd A, Camenzind E, Vrints C, Reifart N, Missault L, Goy JJ, Brinker JA, Raizner AE, Urban P, Heldman AW, Circulation, 109, 487 (2004)
  7. Holmes DR, Leon MB, Moses JW, Popma JJ, Cutlip D, Fitzgerald PJ, Brown C, Fischell T, Wong SC, Midei M, Snead D, Kuntz RE, Circulation, 109, 634 (2004)
  8. Park SJ, Shim WH, Ho DS, Raizner AE, Park SW, Hong MK, Lee CW, Choi D, Jang Y, Lam R, Weissman NJ, Mintz GS, N. Engl. J. Med., 348, 1537 (2003)
  9. Kwon JS, Park SS, Kim YG, Son JH, Lee YS, Kim KS, Hwang KK, Kim DW, Cho MC, Korean Circ. J., 35, 221 (2005)
  10. Park JS, Shin JH, Lee DH, Rhee JM, Kim MS, Lee HB, Khang G, Polym.(Korea), 31(3), 201 (2007)
  11. Kim SH, Lee KS, Kim YH, Choi WJ, Kim BS, Kim EK, Kim DS, Polym.(Korea), 31(2), 153 (2007)
  12. Kim HS, Kim JS, Kim DW, Kang BC, Lee BH, Kim BS, Korean J. Biotechnol. Bioeng., 18, 107 (2003)
  13. Kim JS, Lee BH, Kim BS, Biochem. Eng. J., 23, 169 (2005)
  14. Saito Y, Nakamura S, Hiramitsu M, Doi Y, Polym. Int., 39, 169 (1996)
  15. Dhanikula AB, Panchagnula R, The AAPS J., 11, e27 (2004)
  16. Grant J, Blicker M, Piquette-Miller M, Allen C, The Pharm. Sci., 94, 1512 (2005)
  17. Kelly B, Melhem M, Zhang J, Kasting G, Li J, Krishnamoorthy M, Heffelfinger S, Rudich S, Desai P, Roy-Chaudhury P, Nephrol. Dial. Transplant., 21, 2425 (2006)
  18. Pires NM, van der Hoeven BL, Vries MR, Havekes LM, van Vlijmen BJ, Hennink WE, Quax PH, Jukema JW, Biomaterials, 26, 5386 (2005)
  19. Masaki T, Rathi R, Zentner G, Leypoldt JK, Mohammad SF, Burns GL, Li L, Zhuplatov S, Chirananthavat T, Kim SJ, Kern S, Holman J, Kim SW, Cheung AK, Kidney Int., 66, 2061 (2004)
  20. Jackson JK, Smith J, Letchford K, Babiuk KA, Machan L, Signore P, Hunter WL, Wang K, Burt HM, Int. J. Pharm., 283, 97 (2004)
  21. Goodwin SC, Yoon HC, Chen G, Abdel-Sayed P, Costantino MM, Bonilla SM, Nishimura E, Cardiovasc. Intervent. Radiol., 26, 158 (2003)
  22. van der Giessen WJ, Lincoff AM, Schwartz RS, van Beusekom HM, Serruys PW, Holmes DR, Ellis SG, Topol EJ, Circulation, 94, 1690 (1996)
  23. Acharya G, Park K, Adv. Drug Deliver. Rev., 58, 387 (2006)
  24. Williams SF, Martin DP, “Applications of PHAs in medicine and pharmacy”, in Biopolymers, Polyesters III, Y. Doi and A. Steinbuchel, Editors, Wiley-VCH, Weinheim, p. 91 (2002)
  25. Hwang CW, Wu D, Edelman ER, Circulation, 104, 600 (2001)
  26. Finkelstein A, McClean D, Kar S, Takizawa K, Varghese K, Baek N, Park K, Fishbein MC, Makkar R, Litvack F, Eigler NL, Circulation, 107, 777 (2003)
  27. Creel CJ, Lovich MA, Edelman ER, Circ. Res., 86, 879 (2000)